Sensitization with an allogeneic MHC class I molecule induces anti-tumor immunity in the absence of PD-1 in mice
Abstract
To investigate the effect of a major histocompatibility complex class I (MHC-I) overexpression to augment immune sensitivity against tumors, we have generated the murine colorectal carcinoma cell line MC38 (with the endogenous H-2b haplotype) overexpressing the allogeneic mouse MHC-I cell surface molecule H-2Kd (MC38 H-2Kd). The tumorigenicity of unmodified parental cells (MC38 PT) and MC38 H-2Kd was tested in vivo by subcutaneous injection into the flank of wild-type (WT) and programmed death-1 (PD-1) knockout (KO) mice in a C57BL/6 (H-2b) genetic background. MC38 PT cells readily formed tumors and grew progressively in both WT and PD-1 KO mice. The speed of MC38 PT tumor growth was slower in PD-1 KO mice than in WT mice. In contrast, MC38 H-2Kd cells showed full sensitivity to rejection by the immune system in both naive WT and PD-1 KO mice, indicated by spontaneous tumor regression. Next, we sought to determine the extent to which H-2Kd-overexpressing tumors could protect the mice against unmodified cancers. PD-1 KO mice were first sensitized with highly immunogenic MC38 H-2Kd cells and then challenged with weakly immunogenic MC38 PT cells. Intriguingly, all PD-1 KO mice gained immunity against the aggressive MC38 tumor and became tumor-free. Sensitizing PD-1 KO mice with growth-arrested (by the pre-treatment with mitomycin C, MMC) and the debris of MC38 H-2Kd tumors also provided full protection against the growth of secondary MC38 PT tumors. Most notably, sensitization with the debris of MC38 H-2Kd cells provided the long-term immunological memory against MC38 PT carcinoma cells. This finding implies that MC38 H-2Kd cells retain highly efficient and durable immunogenicity.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy
Josue Estiven Pineda, Tomoyuki Minowa, … Matthew M. Gubin·The Journal of ImmunologyPeer-reviewed·Aug 1, 2026
- PD-L1ATTAC mice reveal the potential of targeting PD-L1 expressing cells in cancer therapy
E. Fueyo-Marcos, C. Fustero-Torre, … M. Murga·bioRxiv·Jul 22, 2022
- Cancer Cell Intrinsic Expression of MHCII Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma
A. M. Johnson, B. L. Bullock, … R. A. Nemenoff·bioRxiv·Jan 9, 2020
- An immunocompetent Merkel cell carcinoma model for preclinical studies
Monique Elise Verhaegen, Simar Bhatia, … Andrzej Antoni Dlugosz·bioRxiv·Jun 26, 2026
- Interferon-γ driven differentiation of monocytes into PD-L1+ and MHC II+ macrophages and the frequency of Tim-3+ tumor-reactive CD8+ T cells within the tumor microenvironment predict a positive response to anti-PD-1-based therapy in tumor-bearing mice
Jelena Gabrilo, Sylvie Vande Velde, … Oberdan Léo·Cancer Immunology ResearchPeer-reviewed·Aug 28, 2025
- Antibody Blockade of Ly49/MHC-I interactions enhances Innate and Adaptive Immunity Against Cancer Metastasis
Abir Kumar Panda, Surajit Sinha, … Ethan M. Shevach·bioRxiv·May 12, 2026